SCHEMBL3610786

SCHEMBL3610786

O=C(O)c1cc2c(F)cc(Br)cc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EIF4A3 P38919 3/20 0.59
GRIN1 Q05586 1/20 0.49
RHEB Q15382 5/20 0.48
IDO1 P14902 3/20 0.46
TDO2 P48775 3/20 0.46
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
HSD17B10 Q99714 2/20 0.45
PDPK1 O15530 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
APEX1 P27695 1/20 0.45
CYP2C19 P33261 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
GPR17 Q13304 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1144892 0.81 EIF4A3 (0.63) EIF4A3GRIN1RHEBIDO1TDO2
SCHEMBL29655546 0.81 EIF4A3 (0.63) EIF4A3GRIN1RHEBIDO1TDO2
SCHEMBL29813002 0.81 EIF4A3 (0.50) EIF4A3GRIN1RHEBKDM4EALDH1A1
SCHEMBL23148149 0.81 EIF4A3 (0.50) EIF4A3GRIN1RHEBKDM4EALDH1A1
SCHEMBL31405949 0.79 KDM4E (0.48) EIF4A3KDM4EALDH1A1LMNAHSD17B10
SCHEMBL4037610 0.79 KDM4E (0.48) EIF4A3KDM4EALDH1A1LMNAHSD17B10
SCHEMBL1144772 0.79 GRIN1 (0.72) EIF4A3GRIN1RHEBIDO1TDO2
SCHEMBL30310414 0.79 GRIN1 (0.72) EIF4A3GRIN1RHEBIDO1TDO2
SCHEMBL23147766 0.79 EIF4A3 (0.64) EIF4A3GRIN1RHEBIDO1TDO2
SCHEMBL21624049 0.77 KDM4E (0.51) EIF4A3GRIN1RHEBIDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11267825-B2 Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) AICURIS GMBH & CO. KG (DE) 2022-03-08 US disclosed
US-20200354379-A1 NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2020-11-12 US disclosed
EP-3704127-A1 NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AiCuris GmbH & Co. KG (DE) 2020-09-09 EP disclosed
CN-111448199-A Novel highly active amino-thiazole-substituted indole-2-carboxamides having activity against Hepatitis B Virus (HBV) 艾库里斯有限及两合公司 2020-07-24 CN disclosed
US-20100035862-A1 NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2010-02-11 US disclosed
WO-2009158375-A1 AZA-CYLIC INDOLE- 2 -CARBOXAMIDES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035862-A1 NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF IDO2, IDO1, INMT EIF4A3 2625/4885GRIN1 650/4885RHEB 2282/4885
US-20200354379-A1 NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) HCCS, CDK2, BRD4 EIF4A3 783/4885GRIN1 3667/4885RHEB 894/4885
US-11267825-B2 Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) HCCS, BRD4, IDO2 EIF4A3 861/4885GRIN1 3329/4885RHEB 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.